F/m Emerald Life Sciences Innovation ETFLFSC
Type
ETF
Peer group
US equity: Healthcare
Net assets
$95.7M
Expense ratio
0.54%
1-year return
+64.4%
3 years, a year
—
5 years, a year
—
Holdings
40
What it aims to do.
The investment objective of the F/m Emerald Life Sciences Innovation ETF (the Fund) is to seek long-term capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| COGT Cogent Biosciences Inc | 9.05% |
| LivaNova PLC | 7.36% |
| TMDX TransMedics Group Inc | 5.26% |
| MIRM Mirum Pharmaceuticals Inc | 4.84% |
| TVTX Travere Therapeutics Inc | 4.63% |
| SYRE Spyre Therapeutics Inc | 4.41% |
| UTHR United Therapeutics Corp | 4.35% |
| GH Guardant Health Inc | 4.32% |
| WaVe Life Sciences Ltd | 4.21% |
| SVRA Savara Inc | 4.04% |
More on LFSC.
- LFSC overview
- LFSC holdings
- LFSC risk
- LFSC costs
- LFSC money in and out
- LFSC share classes
- Compare LFSC with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.